 | • レポートコード：GIR-107A12615 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、123ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥487,200 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥730,800 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥974,400 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、原発性硬化性胆管炎治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。原発性硬化性胆管炎治療の種類別市場規模（肝移植手術、UDCA薬、PSC薬）、用途別市場規模（病院、クリニック、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・原発性硬化性胆管炎治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Allergan、Glenmark、Impax Laboratories、Mylan、Teva Pharmaceuticals、Dr. Falk Pharma、Daewoong Pharmaceutical、Epic Pharma、Mitsubishi Tanabe Pharma、Lannett、Bruschettini、Shanghai Pharma、Grindeks、Acorda Therapeutics、Gilead Sciences、Intercept Pharmaceuticals、Shire Plc、NGM Biopharmaceuticals、Conatus Pharmaceuticals、Durect Corporation、Sirnaomics、Shenzhen HighTide Biopharmaceuticals ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：肝移植手術、UDCA薬、PSC薬 ・用途別分析2016年-2026年：病院、クリニック、その他 ・原発性硬化性胆管炎治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・原発性硬化性胆管炎治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・原発性硬化性胆管炎治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・原発性硬化性胆管炎治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・原発性硬化性胆管炎治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Primary Sclerosing Cholangitis Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Primary Sclerosing Cholangitis Treatment size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Primary Sclerosing Cholangitis Treatment market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Primary Sclerosing Cholangitis Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Liver Transplantation Operation
UDCA Drugs
PSC Drugs
Market segment by Application, can be divided into
Hospital
Clinics
Other
Market segment by players, this report covers
Allergan
Glenmark
Impax Laboratories
Mylan
Teva Pharmaceuticals
Dr. Falk Pharma
Daewoong Pharmaceutical
Epic Pharma
Mitsubishi Tanabe Pharma
Lannett
Bruschettini
Shanghai Pharma
Grindeks
Acorda Therapeutics
Gilead Sciences
Intercept Pharmaceuticals
Shire Plc
NGM Biopharmaceuticals
Conatus Pharmaceuticals
Durect Corporation
Sirnaomics
Shenzhen HighTide Biopharmaceuticals
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Primary Sclerosing Cholangitis Treatment
1.2 Classification of Primary Sclerosing Cholangitis Treatment by Type
1.2.1 Overview: Global Primary Sclerosing Cholangitis Treatment Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Type in 2020
1.2.3 Liver Transplantation Operation
1.2.4 UDCA Drugs
1.2.5 PSC Drugs
1.3 Global Primary Sclerosing Cholangitis Treatment Market by Application
1.3.1 Overview: Global Primary Sclerosing Cholangitis Treatment Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Other
1.4 Global Primary Sclerosing Cholangitis Treatment Market Size & Forecast
1.5 Global Primary Sclerosing Cholangitis Treatment Market Size and Forecast by Region
1.5.1 Global Primary Sclerosing Cholangitis Treatment Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Primary Sclerosing Cholangitis Treatment Market Size by Region, (2016-2021)
1.5.3 North America Primary Sclerosing Cholangitis Treatment Market Size and Prospect (2016-2026)
1.5.4 Europe Primary Sclerosing Cholangitis Treatment Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size and Prospect (2016-2026)
1.5.6 South America Primary Sclerosing Cholangitis Treatment Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Primary Sclerosing Cholangitis Treatment Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Primary Sclerosing Cholangitis Treatment Market Drivers
1.6.2 Primary Sclerosing Cholangitis Treatment Market Restraints
1.6.3 Primary Sclerosing Cholangitis Treatment Trends Analysis
2 Company Profiles
2.1 Allergan
2.1.1 Allergan Details
2.1.2 Allergan Major Business
2.1.3 Allergan Primary Sclerosing Cholangitis Treatment Product and Solutions
2.1.4 Allergan Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Allergan Recent Developments and Future Plans
2.2 Glenmark
2.2.1 Glenmark Details
2.2.2 Glenmark Major Business
2.2.3 Glenmark Primary Sclerosing Cholangitis Treatment Product and Solutions
2.2.4 Glenmark Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Glenmark Recent Developments and Future Plans
2.3 Impax Laboratories
2.3.1 Impax Laboratories Details
2.3.2 Impax Laboratories Major Business
2.3.3 Impax Laboratories Primary Sclerosing Cholangitis Treatment Product and Solutions
2.3.4 Impax Laboratories Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Impax Laboratories Recent Developments and Future Plans
2.4 Mylan
2.4.1 Mylan Details
2.4.2 Mylan Major Business
2.4.3 Mylan Primary Sclerosing Cholangitis Treatment Product and Solutions
2.4.4 Mylan Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Mylan Recent Developments and Future Plans
2.5 Teva Pharmaceuticals
2.5.1 Teva Pharmaceuticals Details
2.5.2 Teva Pharmaceuticals Major Business
2.5.3 Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product and Solutions
2.5.4 Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Teva Pharmaceuticals Recent Developments and Future Plans
2.6 Dr. Falk Pharma
2.6.1 Dr. Falk Pharma Details
2.6.2 Dr. Falk Pharma Major Business
2.6.3 Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Product and Solutions
2.6.4 Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Dr. Falk Pharma Recent Developments and Future Plans
2.7 Daewoong Pharmaceutical
2.7.1 Daewoong Pharmaceutical Details
2.7.2 Daewoong Pharmaceutical Major Business
2.7.3 Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Product and Solutions
2.7.4 Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Daewoong Pharmaceutical Recent Developments and Future Plans
2.8 Epic Pharma
2.8.1 Epic Pharma Details
2.8.2 Epic Pharma Major Business
2.8.3 Epic Pharma Primary Sclerosing Cholangitis Treatment Product and Solutions
2.8.4 Epic Pharma Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Epic Pharma Recent Developments and Future Plans
2.9 Mitsubishi Tanabe Pharma
2.9.1 Mitsubishi Tanabe Pharma Details
2.9.2 Mitsubishi Tanabe Pharma Major Business
2.9.3 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Product and Solutions
2.9.4 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Mitsubishi Tanabe Pharma Recent Developments and Future Plans
2.10 Lannett
2.10.1 Lannett Details
2.10.2 Lannett Major Business
2.10.3 Lannett Primary Sclerosing Cholangitis Treatment Product and Solutions
2.10.4 Lannett Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Lannett Recent Developments and Future Plans
2.11 Bruschettini
2.11.1 Bruschettini Details
2.11.2 Bruschettini Major Business
2.11.3 Bruschettini Primary Sclerosing Cholangitis Treatment Product and Solutions
2.11.4 Bruschettini Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Bruschettini Recent Developments and Future Plans
2.12 Shanghai Pharma
2.12.1 Shanghai Pharma Details
2.12.2 Shanghai Pharma Major Business
2.12.3 Shanghai Pharma Primary Sclerosing Cholangitis Treatment Product and Solutions
2.12.4 Shanghai Pharma Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Shanghai Pharma Recent Developments and Future Plans
2.13 Grindeks
2.13.1 Grindeks Details
2.13.2 Grindeks Major Business
2.13.3 Grindeks Primary Sclerosing Cholangitis Treatment Product and Solutions
2.13.4 Grindeks Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Grindeks Recent Developments and Future Plans
2.14 Acorda Therapeutics
2.14.1 Acorda Therapeutics Details
2.14.2 Acorda Therapeutics Major Business
2.14.3 Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Product and Solutions
2.14.4 Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 Acorda Therapeutics Recent Developments and Future Plans
2.15 Gilead Sciences
2.15.1 Gilead Sciences Details
2.15.2 Gilead Sciences Major Business
2.15.3 Gilead Sciences Primary Sclerosing Cholangitis Treatment Product and Solutions
2.15.4 Gilead Sciences Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.15.5 Gilead Sciences Recent Developments and Future Plans
2.16 Intercept Pharmaceuticals
2.16.1 Intercept Pharmaceuticals Details
2.16.2 Intercept Pharmaceuticals Major Business
2.16.3 Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product and Solutions
2.16.4 Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.16.5 Intercept Pharmaceuticals Recent Developments and Future Plans
2.17 Shire Plc
2.17.1 Shire Plc Details
2.17.2 Shire Plc Major Business
2.17.3 Shire Plc Primary Sclerosing Cholangitis Treatment Product and Solutions
2.17.4 Shire Plc Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.17.5 Shire Plc Recent Developments and Future Plans
2.18 NGM Biopharmaceuticals
2.18.1 NGM Biopharmaceuticals Details
2.18.2 NGM Biopharmaceuticals Major Business
2.18.3 NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Product and Solutions
2.18.4 NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.18.5 NGM Biopharmaceuticals Recent Developments and Future Plans
2.19 Conatus Pharmaceuticals
2.19.1 Conatus Pharmaceuticals Details
2.19.2 Conatus Pharmaceuticals Major Business
2.19.3 Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product and Solutions
2.19.4 Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.19.5 Conatus Pharmaceuticals Recent Developments and Future Plans
2.20 Durect Corporation
2.20.1 Durect Corporation Details
2.20.2 Durect Corporation Major Business
2.20.3 Durect Corporation Primary Sclerosing Cholangitis Treatment Product and Solutions
2.20.4 Durect Corporation Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.20.5 Durect Corporation Recent Developments and Future Plans
2.21 Sirnaomics
2.21.1 Sirnaomics Details
2.21.2 Sirnaomics Major Business
2.21.3 Sirnaomics Primary Sclerosing Cholangitis Treatment Product and Solutions
2.21.4 Sirnaomics Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.21.5 Sirnaomics Recent Developments and Future Plans
2.22 Shenzhen HighTide Biopharmaceuticals
2.22.1 Shenzhen HighTide Biopharmaceuticals Details
2.22.2 Shenzhen HighTide Biopharmaceuticals Major Business
2.22.3 Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Product and Solutions
2.22.4 Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.22.5 Shenzhen HighTide Biopharmaceuticals Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Primary Sclerosing Cholangitis Treatment Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Primary Sclerosing Cholangitis Treatment Players Market Share
3.2.2 Top 10 Primary Sclerosing Cholangitis Treatment Players Market Share
3.2.3 Market Competition Trend
3.3 Primary Sclerosing Cholangitis Treatment Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Primary Sclerosing Cholangitis Treatment Revenue and Market Share by Type (2016-2021)
4.2 Global Primary Sclerosing Cholangitis Treatment Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Application (2016-2021)
5.2 Primary Sclerosing Cholangitis Treatment Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Primary Sclerosing Cholangitis Treatment Revenue by Type (2016-2026)
6.2 North America Primary Sclerosing Cholangitis Treatment Revenue by Application (2016-2026)
6.3 North America Primary Sclerosing Cholangitis Treatment Market Size by Country
6.3.1 North America Primary Sclerosing Cholangitis Treatment Revenue by Country (2016-2026)
6.3.2 United States Primary Sclerosing Cholangitis Treatment Market Size and Forecast (2016-2026)
6.3.3 Canada Primary Sclerosing Cholangitis Treatment Market Size and Forecast (2016-2026)
6.3.4 Mexico Primary Sclerosing Cholangitis Treatment Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Primary Sclerosing Cholangitis Treatment Revenue by Type (2016-2026)
7.2 Europe Primary Sclerosing Cholangitis Treatment Revenue by Application (2016-2026)
7.3 Europe Primary Sclerosing Cholangitis Treatment Market Size by Country
7.3.1 Europe Primary Sclerosing Cholangitis Treatment Revenue by Country (2016-2026)
7.3.2 Germany Primary Sclerosing Cholangitis Treatment Market Size and Forecast (2016-2026)
7.3.3 France Primary Sclerosing Cholangitis Treatment Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Primary Sclerosing Cholangitis Treatment Market Size and Forecast (2016-2026)
7.3.5 Russia Primary Sclerosing Cholangitis Treatment Market Size and Forecast (2016-2026)
7.3.6 Italy Primary Sclerosing Cholangitis Treatment Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Primary Sclerosing Cholangitis Treatment Revenue by Type (2016-2026)
8.2 Asia-Pacific Primary Sclerosing Cholangitis Treatment Revenue by Application (2016-2026)
8.3 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Region
8.3.1 Asia-Pacific Primary Sclerosing Cholangitis Treatment Revenue by Region (2016-2026)
8.3.2 China Primary Sclerosing Cholangitis Treatment Market Size and Forecast (2016-2026)
8.3.3 Japan Primary Sclerosing Cholangitis Treatment Market Size and Forecast (2016-2026)
8.3.4 South Korea Primary Sclerosing Cholangitis Treatment Market Size and Forecast (2016-2026)
8.3.5 India Primary Sclerosing Cholangitis Treatment Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Primary Sclerosing Cholangitis Treatment Market Size and Forecast (2016-2026)
8.3.7 Australia Primary Sclerosing Cholangitis Treatment Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Primary Sclerosing Cholangitis Treatment Revenue by Type (2016-2026)
9.2 South America Primary Sclerosing Cholangitis Treatment Revenue by Application (2016-2026)
9.3 South America Primary Sclerosing Cholangitis Treatment Market Size by Country
9.3.1 South America Primary Sclerosing Cholangitis Treatment Revenue by Country (2016-2026)
9.3.2 Brazil Primary Sclerosing Cholangitis Treatment Market Size and Forecast (2016-2026)
9.3.3 Argentina Primary Sclerosing Cholangitis Treatment Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Primary Sclerosing Cholangitis Treatment Revenue by Type (2016-2026)
10.2 Middle East & Africa Primary Sclerosing Cholangitis Treatment Revenue by Application (2016-2026)
10.3 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Country
10.3.1 Middle East & Africa Primary Sclerosing Cholangitis Treatment Revenue by Country (2016-2026)
10.3.2 Turkey Primary Sclerosing Cholangitis Treatment Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Primary Sclerosing Cholangitis Treatment Market Size and Forecast (2016-2026)
10.3.4 UAE Primary Sclerosing Cholangitis Treatment Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Primary Sclerosing Cholangitis Treatment Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Primary Sclerosing Cholangitis Treatment Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Primary Sclerosing Cholangitis Treatment Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Primary Sclerosing Cholangitis Treatment Revenue (USD Million) by Region (2016-2021)
Table 5. Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Region (2021-2026)
Table 6. Allergan Corporate Information, Head Office, and Major Competitors
Table 7. Allergan Major Business
Table 8. Allergan Primary Sclerosing Cholangitis Treatment Product and Solutions
Table 9. Allergan Primary Sclerosing Cholangitis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Glenmark Corporate Information, Head Office, and Major Competitors
Table 11. Glenmark Major Business
Table 12. Glenmark Primary Sclerosing Cholangitis Treatment Product and Solutions
Table 13. Glenmark Primary Sclerosing Cholangitis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Impax Laboratories Corporate Information, Head Office, and Major Competitors
Table 15. Impax Laboratories Major Business
Table 16. Impax Laboratories Primary Sclerosing Cholangitis Treatment Product and Solutions
Table 17. Impax Laboratories Primary Sclerosing Cholangitis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Mylan Corporate Information, Head Office, and Major Competitors
Table 19. Mylan Major Business
Table 20. Mylan Primary Sclerosing Cholangitis Treatment Product and Solutions
Table 21. Mylan Primary Sclerosing Cholangitis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Teva Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 23. Teva Pharmaceuticals Major Business
Table 24. Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product and Solutions
Table 25. Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Dr. Falk Pharma Corporate Information, Head Office, and Major Competitors
Table 27. Dr. Falk Pharma Major Business
Table 28. Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Product and Solutions
Table 29. Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Daewoong Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 31. Daewoong Pharmaceutical Major Business
Table 32. Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Product and Solutions
Table 33. Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Epic Pharma Corporate Information, Head Office, and Major Competitors
Table 35. Epic Pharma Major Business
Table 36. Epic Pharma Primary Sclerosing Cholangitis Treatment Product and Solutions
Table 37. Epic Pharma Primary Sclerosing Cholangitis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Mitsubishi Tanabe Pharma Corporate Information, Head Office, and Major Competitors
Table 39. Mitsubishi Tanabe Pharma Major Business
Table 40. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Product and Solutions
Table 41. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Lannett Corporate Information, Head Office, and Major Competitors
Table 43. Lannett Major Business
Table 44. Lannett Primary Sclerosing Cholangitis Treatment Product and Solutions
Table 45. Lannett Primary Sclerosing Cholangitis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Bruschettini Corporate Information, Head Office, and Major Competitors
Table 47. Bruschettini Major Business
Table 48. Bruschettini Primary Sclerosing Cholangitis Treatment Product and Solutions
Table 49. Bruschettini Primary Sclerosing Cholangitis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Shanghai Pharma Corporate Information, Head Office, and Major Competitors
Table 51. Shanghai Pharma Major Business
Table 52. Shanghai Pharma Primary Sclerosing Cholangitis Treatment Product and Solutions
Table 53. Shanghai Pharma Primary Sclerosing Cholangitis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Grindeks Corporate Information, Head Office, and Major Competitors
Table 55. Grindeks Major Business
Table 56. Grindeks Primary Sclerosing Cholangitis Treatment Product and Solutions
Table 57. Grindeks Primary Sclerosing Cholangitis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. Acorda Therapeutics Corporate Information, Head Office, and Major Competitors
Table 59. Acorda Therapeutics Major Business
Table 60. Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Product and Solutions
Table 61. Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 62. Gilead Sciences Corporate Information, Head Office, and Major Competitors
Table 63. Gilead Sciences Major Business
Table 64. Gilead Sciences Primary Sclerosing Cholangitis Treatment Product and Solutions
Table 65. Gilead Sciences Primary Sclerosing Cholangitis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 66. Intercept Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 67. Intercept Pharmaceuticals Major Business
Table 68. Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product and Solutions
Table 69. Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 70. Shire Plc Corporate Information, Head Office, and Major Competitors
Table 71. Shire Plc Major Business
Table 72. Shire Plc Primary Sclerosing Cholangitis Treatment Product and Solutions
Table 73. Shire Plc Primary Sclerosing Cholangitis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 74. NGM Biopharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 75. NGM Biopharmaceuticals Major Business
Table 76. NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Product and Solutions
Table 77. NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 78. Conatus Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 79. Conatus Pharmaceuticals Major Business
Table 80. Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product and Solutions
Table 81. Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 82. Durect Corporation Corporate Information, Head Office, and Major Competitors
Table 83. Durect Corporation Major Business
Table 84. Durect Corporation Primary Sclerosing Cholangitis Treatment Product and Solutions
Table 85. Durect Corporation Primary Sclerosing Cholangitis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 86. Sirnaomics Corporate Information, Head Office, and Major Competitors
Table 87. Sirnaomics Major Business
Table 88. Sirnaomics Primary Sclerosing Cholangitis Treatment Product and Solutions
Table 89. Sirnaomics Primary Sclerosing Cholangitis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 90. Shenzhen HighTide Biopharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 91. Shenzhen HighTide Biopharmaceuticals Major Business
Table 92. Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Product and Solutions
Table 93. Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 94. Global Primary Sclerosing Cholangitis Treatment Revenue (USD Million) by Players (2019-2021)
Table 95. Global Primary Sclerosing Cholangitis Treatment Revenue Share by Players (2019-2021)
Table 96. Breakdown of Primary Sclerosing Cholangitis Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 97. Primary Sclerosing Cholangitis Treatment Players Head Office, Products and Services Provided
Table 98. Primary Sclerosing Cholangitis Treatment Mergers & Acquisitions in the Past Five Years
Table 99. Primary Sclerosing Cholangitis Treatment New Entrants and Expansion Plans
Table 100. Global Primary Sclerosing Cholangitis Treatment Revenue (USD Million) by Type (2016-2021)
Table 101. Global Primary Sclerosing Cholangitis Treatment Revenue Share by Type (2016-2021)
Table 102. Global Primary Sclerosing Cholangitis Treatment Revenue Forecast by Type (2021-2026)
Table 103. Global Primary Sclerosing Cholangitis Treatment Revenue by Application (2016-2021)
Table 104. Global Primary Sclerosing Cholangitis Treatment Revenue Forecast by Application (2021-2026)
Table 105. North America Primary Sclerosing Cholangitis Treatment Revenue by Type (2016-2021) & (USD Million)
Table 106. North America Primary Sclerosing Cholangitis Treatment Revenue by Type (2021-2026) & (USD Million)
Table 107. North America Primary Sclerosing Cholangitis Treatment Revenue by Application (2016-2021) & (USD Million)
Table 108. North America Primary Sclerosing Cholangitis Treatment Revenue by Application (2021-2026) & (USD Million)
Table 109. North America Primary Sclerosing Cholangitis Treatment Revenue by Country (2016-2021) & (USD Million)
Table 110. North America Primary Sclerosing Cholangitis Treatment Revenue by Country (2021-2026) & (USD Million)
Table 111. Europe Primary Sclerosing Cholangitis Treatment Revenue by Type (2016-2021) & (USD Million)
Table 112. Europe Primary Sclerosing Cholangitis Treatment Revenue by Type (2021-2026) & (USD Million)
Table 113. Europe Primary Sclerosing Cholangitis Treatment Revenue by Application (2016-2021) & (USD Million)
Table 114. Europe Primary Sclerosing Cholangitis Treatment Revenue by Application (2021-2026) & (USD Million)
Table 115. Europe Primary Sclerosing Cholangitis Treatment Revenue by Country (2016-2021) & (USD Million)
Table 116. Europe Primary Sclerosing Cholangitis Treatment Revenue by Country (2021-2026) & (USD Million)
Table 117. Asia-Pacific Primary Sclerosing Cholangitis Treatment Revenue by Type (2016-2021) & (USD Million)
Table 118. Asia-Pacific Primary Sclerosing Cholangitis Treatment Revenue by Type (2021-2026) & (USD Million)
Table 119. Asia-Pacific Primary Sclerosing Cholangitis Treatment Revenue by Application (2016-2021) & (USD Million)
Table 120. Asia-Pacific Primary Sclerosing Cholangitis Treatment Revenue by Application (2021-2026) & (USD Million)
Table 121. Asia-Pacific Primary Sclerosing Cholangitis Treatment Revenue by Region (2016-2021) & (USD Million)
Table 122. Asia-Pacific Primary Sclerosing Cholangitis Treatment Revenue by Region (2021-2026) & (USD Million)
Table 123. South America Primary Sclerosing Cholangitis Treatment Revenue by Type (2016-2021) & (USD Million)
Table 124. South America Primary Sclerosing Cholangitis Treatment Revenue by Type (2021-2026) & (USD Million)
Table 125. South America Primary Sclerosing Cholangitis Treatment Revenue by Application (2016-2021) & (USD Million)
Table 126. South America Primary Sclerosing Cholangitis Treatment Revenue by Application (2021-2026) & (USD Million)
Table 127. South America Primary Sclerosing Cholangitis Treatment Revenue by Country (2016-2021) & (USD Million)
Table 128. South America Primary Sclerosing Cholangitis Treatment Revenue by Country (2021-2026) & (USD Million)
Table 129. Middle East & Africa Primary Sclerosing Cholangitis Treatment Revenue by Type (2016-2021) & (USD Million)
Table 130. Middle East & Africa Primary Sclerosing Cholangitis Treatment Revenue by Type (2021-2026) & (USD Million)
Table 131. Middle East & Africa Primary Sclerosing Cholangitis Treatment Revenue by Application (2016-2021) & (USD Million)
Table 132. Middle East & Africa Primary Sclerosing Cholangitis Treatment Revenue by Application (2021-2026) & (USD Million)
Table 133. Middle East & Africa Primary Sclerosing Cholangitis Treatment Revenue by Country (2016-2021) & (USD Million)
Table 134. Middle East & Africa Primary Sclerosing Cholangitis Treatment Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Primary Sclerosing Cholangitis Treatment Picture
Figure 2. Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Type in 2020
Figure 3. Liver Transplantation Operation
Figure 4. UDCA Drugs
Figure 5. PSC Drugs
Figure 6. Primary Sclerosing Cholangitis Treatment Revenue Market Share by Application in 2020
Figure 7. Hospital Picture
Figure 8. Clinics Picture
Figure 9. Other Picture
Figure 10. Global Primary Sclerosing Cholangitis Treatment Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 11. Global Primary Sclerosing Cholangitis Treatment Revenue and Forecast (2016-2026) & (USD Million)
Figure 12. Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Region (2016-2026)
Figure 13. Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Region in 2020
Figure 14. North America Primary Sclerosing Cholangitis Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Europe Primary Sclerosing Cholangitis Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Asia-Pacific Primary Sclerosing Cholangitis Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. South America Primary Sclerosing Cholangitis Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Middle East and Africa Primary Sclerosing Cholangitis Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Primary Sclerosing Cholangitis Treatment Market Drivers
Figure 20. Primary Sclerosing Cholangitis Treatment Market Restraints
Figure 21. Primary Sclerosing Cholangitis Treatment Market Trends
Figure 22. Allergan Recent Developments and Future Plans
Figure 23. Glenmark Recent Developments and Future Plans
Figure 24. Impax Laboratories Recent Developments and Future Plans
Figure 25. Mylan Recent Developments and Future Plans
Figure 26. Teva Pharmaceuticals Recent Developments and Future Plans
Figure 27. Dr. Falk Pharma Recent Developments and Future Plans
Figure 28. Daewoong Pharmaceutical Recent Developments and Future Plans
Figure 29. Epic Pharma Recent Developments and Future Plans
Figure 30. Mitsubishi Tanabe Pharma Recent Developments and Future Plans
Figure 31. Lannett Recent Developments and Future Plans
Figure 32. Bruschettini Recent Developments and Future Plans
Figure 33. Shanghai Pharma Recent Developments and Future Plans
Figure 34. Grindeks Recent Developments and Future Plans
Figure 35. Acorda Therapeutics Recent Developments and Future Plans
Figure 36. Gilead Sciences Recent Developments and Future Plans
Figure 37. Intercept Pharmaceuticals Recent Developments and Future Plans
Figure 38. Shire Plc Recent Developments and Future Plans
Figure 39. NGM Biopharmaceuticals Recent Developments and Future Plans
Figure 40. Conatus Pharmaceuticals Recent Developments and Future Plans
Figure 41. Durect Corporation Recent Developments and Future Plans
Figure 42. Sirnaomics Recent Developments and Future Plans
Figure 43. Shenzhen HighTide Biopharmaceuticals Recent Developments and Future Plans
Figure 44. Global Primary Sclerosing Cholangitis Treatment Revenue Share by Players in 2020
Figure 45. Primary Sclerosing Cholangitis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 46. Global Top 3 Players Primary Sclerosing Cholangitis Treatment Revenue Market Share in 2020
Figure 47. Global Top 10 Players Primary Sclerosing Cholangitis Treatment Revenue Market Share in 2020
Figure 48. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 49. Global Primary Sclerosing Cholangitis Treatment Revenue Share by Type in 2020
Figure 50. Global Primary Sclerosing Cholangitis Treatment Market Share Forecast by Type (2021-2026)
Figure 51. Global Primary Sclerosing Cholangitis Treatment Revenue Share by Application in 2020
Figure 52. Global Primary Sclerosing Cholangitis Treatment Market Share Forecast by Application (2021-2026)
Figure 53. North America Primary Sclerosing Cholangitis Treatment Sales Market Share by Type (2016-2026)
Figure 54. North America Primary Sclerosing Cholangitis Treatment Sales Market Share by Application (2016-2026)
Figure 55. North America Primary Sclerosing Cholangitis Treatment Revenue Market Share by Country (2016-2026)
Figure 56. United States Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Canada Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Mexico Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Europe Primary Sclerosing Cholangitis Treatment Sales Market Share by Type (2016-2026)
Figure 60. Europe Primary Sclerosing Cholangitis Treatment Sales Market Share by Application (2016-2026)
Figure 61. Europe Primary Sclerosing Cholangitis Treatment Revenue Market Share by Country (2016-2026)
Figure 62. Germany Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. France Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. United Kingdom Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Russia Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. Italy Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Asia-Pacific Primary Sclerosing Cholangitis Treatment Sales Market Share by Type (2016-2026)
Figure 68. Asia-Pacific Primary Sclerosing Cholangitis Treatment Sales Market Share by Application (2016-2026)
Figure 69. Asia-Pacific Primary Sclerosing Cholangitis Treatment Revenue Market Share by Region (2016-2026)
Figure 70. China Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Japan Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. South Korea Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. India Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Southeast Asia Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Australia Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. South America Primary Sclerosing Cholangitis Treatment Sales Market Share by Type (2016-2026)
Figure 77. South America Primary Sclerosing Cholangitis Treatment Sales Market Share by Application (2016-2026)
Figure 78. South America Primary Sclerosing Cholangitis Treatment Revenue Market Share by Country (2016-2026)
Figure 79. Brazil Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. Argentina Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 81. Middle East and Africa Primary Sclerosing Cholangitis Treatment Sales Market Share by Type (2016-2026)
Figure 82. Middle East and Africa Primary Sclerosing Cholangitis Treatment Sales Market Share by Application (2016-2026)
Figure 83. Middle East and Africa Primary Sclerosing Cholangitis Treatment Revenue Market Share by Country (2016-2026)
Figure 84. Turkey Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 85. Saudi Arabia Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 86. UAE Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 87. Methodology
Figure 88. Research Process and Data Source
世界の原発性胆管胆管炎治療市場予測（～2024年） Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is an autoimmune disease of the liver. It results from a slow, progressive destruction of the small bile ducts of the liver, causing bile and other toxins to build up in the liver, a condition called cholestasis. There…- 世界の一次破砕機市場 2021：企業別、地域別、種類・用途別 The Primary Crushers market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, r…
- 世界の一次電池のリサイクル市場予測（～2024年）：企業別、地域別、種類・用途別 Primary Battery Recycling is a recycling activity that aims to reduce the number of batteries being disposed as municipal solid waste. Scope of the Report: The global Primary Battery Recycling market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, grow…
- 世界の一次抗体市場 2021：企業別、地域別、種類・用途別 The Primary Antibody market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, r…
- 世界の多発性硬化症治療薬・治療市場 2021：企業別、地域別、種類・用途別 The Multiple Sclerosis Drugs Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, tr…